SymBiosis Capital Partners, LLC — 13F Holdings & Portfolio
CIK 2006045 · latest 13F-HR filed 2026-05-12
SymBiosis Capital Partners, LLC manages $52.8M in 13F-reported U.S. long-equity assets across 6 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are EVMN (55.80%), IVA (24.76%), WVE (10.30%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 6, added to 2, and trimmed 3.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$52.8M
Long-equity book
6
Distinct positions
2026-03-31
Filed 2026-05-12
+1 / −6 / ↑2 / ↓3
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Trims
- Rani Therapeutics Holdings, Inc.-$5.8M -68.3%
- Clene Nanomedicine Inc.-$2.4M -53.0%
- Surrozen, Inc.-$600 -20.0%
Exited Positions
- Verastem Inc$15.4M
- Aldeyra Therapeutics Inc$13.2M
- Precigen Inc$12.5M
- Nuvation Bio Inc$11.2M
- Aardvark Therapeutics, Inc.$6.3M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Evommune, Inc. | EVMN | 30054Y107 | $29.4M | 55.80% | 1,280,778 | SH |
| 2 | Inventiva S.A. | IVA | 46124U107 | $13.1M | 24.76% | 2,354,000 | SH |
| 3 | Wave Life Sciences Ltd. | WVE | Y95308105 | $5.4M | 10.30% | 750,000 | SH |
| 4 | Rani Therapeutics Holdings, Inc. | RANI | 753018100 | $2.7M | 5.11% | 3,667,585 | SH |
| 5 | Clene Nanomedicine Inc. | CLNN | 185634201 | $2.1M | 4.03% | 431,094 | SH |
| 6 | Surrozen, Inc. | SRZNW | 86889P117 | $2.4K | 0.00% | 150,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | $52.8M | 6 | 0002006045-26-000007 |
| 2025-12-31 | 2026-02-12 | $109.5M | 11 | 0002006045-26-000002 |